These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Oral therapy with beta-2-sympathomimetic drugs: comparative study of the bronchospasmolytic effect of tulobuterol and fenoterol in patients with reversible airway obstruction]. Morr H; Nink M; Ferlinz R Pneumologie; 1990 Apr; 44(4):739-43. PubMed ID: 2192369 [TBL] [Abstract][Full Text] [Related]
6. [Comparative studies on the effectiveness of inhalant beta 2 mimetics therapy in patients with obstructive respiratory disorders]. Würtemberger G; Weil R; Schulte-Mönting J; Matthys H Prax Klin Pneumol; 1988 Jun; 42 Suppl 1():304-6. PubMed ID: 2902608 [No Abstract] [Full Text] [Related]
7. Comparison of the effects of tulobuterol patch and salmeterol in moderate to severe asthma. Nishiyama O; Taniguchi H; Kondoh Y; Kimura T; Kato K; Kume H; Shimokata K Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1016-21. PubMed ID: 17042908 [TBL] [Abstract][Full Text] [Related]
8. Effects of a combined treatment theophylline and tulobuterol on nocturnal chronic asthma. Rühle KH; Dorow P; Schmitz-Schumann H Lung; 1990; 168 Suppl():192-3. PubMed ID: 1974676 [No Abstract] [Full Text] [Related]
10. [Pulmonary function tests in asthmatic children in treatment with tulobuterol]. Pérez-Martini L; Blanco RA; Heffner G; Ordóñez-Comparini R Bol Med Hosp Infant Mex; 1989 Apr; 46(4):241-5. PubMed ID: 2719810 [TBL] [Abstract][Full Text] [Related]
11. Maintenance therapy for obstructive lung disease. How to achieve the best response with the fewest agents. Jacobs M Postgrad Med; 1994 Jun; 95(8):87-90, 93-6, 99. PubMed ID: 8202425 [TBL] [Abstract][Full Text] [Related]
12. Pharmacotherapy for asthma and chronic obstructive pulmonary disease. Current thinking, practices, and controversies. Skorodin MS Arch Intern Med; 1993 Apr; 153(7):814-28. PubMed ID: 8096690 [TBL] [Abstract][Full Text] [Related]
13. The use of patch formulation of tulobuterol, a long-acting beta2-adrenoreceptor agonist, in the treatment of severe pediatric asthma. Yoshihara S; Yamada Y; Abe T; Arisaka O Ann Allergy Asthma Immunol; 2006 Jun; 96(6):879-80. PubMed ID: 16802779 [No Abstract] [Full Text] [Related]
14. Influence of different extension-actuator tubes on the bronchodilation effect of a terbutaline sulfate aerosol. Lulling J; Delwiche JP; Hidinger KG; Prignot J Eur J Respir Dis; 1983 Jan; 64(1):33-7. PubMed ID: 6825747 [TBL] [Abstract][Full Text] [Related]
15. Addition of transdermal or inhaled long-acting Beta2-agonists in adult asthmatic patients treated with inhaled corticosteroids: switchover study from tulobuterol patch to salmeterol dry powder inhaler. Kobayashi Y; Yasuba H; Kudou M; Kita H J Asthma; 2007 Mar; 44(2):77-81. PubMed ID: 17454319 [TBL] [Abstract][Full Text] [Related]
17. [Kombipek in the therapy of patients with broncho-obstructive lung diseases]. Chuchalin AG; Tsoĭ AN; Zaĭtseva TM; Titova EV; Medani SM; Smirnov MV; Kaziakhmedov EA Ter Arkh; 1995; 67(6):26-9. PubMed ID: 7667774 [TBL] [Abstract][Full Text] [Related]
18. [Lung function studies with the bronchodilator terbutaline]. Kaik G; Bonelli J; Hitzenberger G; Laggner A; Magometschnigg D Acta Med Austriaca; 1979; 6(2):1-39. PubMed ID: 517068 [TBL] [Abstract][Full Text] [Related]
19. Prolonged treatment with oral and inhaled tulobuterol does not induce airways tachyphlaxis. Patel KR Lung; 1990; 168 Suppl():210-8. PubMed ID: 1974679 [TBL] [Abstract][Full Text] [Related]
20. The role of patient-centered outcomes in the course of chronic obstructive pulmonary disease: how long-term studies contribute to our understanding. Tashkin DP Am J Med; 2006 Oct; 119(10 Suppl 1):63-72. PubMed ID: 16996901 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]